HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $620

Madrigal Pharmaceuticals, Inc. -1.52%

Madrigal Pharmaceuticals, Inc.

MDGL

577.30

-1.52%

HC Wainwright & Co. analyst Andrew S. Fein maintains Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy and raises the price target from $568 to $620.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via